Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

Medical oncology (Northwood, London, England) - 1 Sept 2012

Xu Min, Fan Lei, Miao Kou-Rong, Liu Peng, Xu Wei, Li Jian-Yong

Abstract excerpt

To determine whether prognostic factors remain relevant to chronic lymphocytic leukemia (CLL) patients treated with fludarabine and cyclophosphamide (FC), we prospectively evaluated 86 Chinese CLL patients who received FC in first-line therapy. Twenty-four patients (27.9%) achieved complete remission (CR), and overall response rate was 75.6%. With a median follow-up of 41 months, the median progression-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Disease-Free Survival

Share to Genes, Immunoglobulin Heavy Chain

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Vidarabine

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Identifiers

PMID: 21881978
DOI: 10.1007/s12032-011-0054-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.PMID 21881978Read ↗

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.Semantic proximity Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.Semantic proximity Read ↗

[Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].Semantic proximity Read ↗

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Semantic proximity Read ↗

[Clinical analysis on 40 patients with chronic lymphocytic leukemia].Semantic proximity Read ↗

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.Semantic proximity Read ↗

Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy.Semantic proximity Read ↗

Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.